Key terms
About TECH
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TECH news
Apr 18
5:36am ET
Bio-Techne price target lowered to $82 from $85 at Deutsche Bank
Apr 08
9:46pm ET
RBC Capital Reaffirms Their Hold Rating on Bio-Techne (TECH)
Apr 04
5:45am ET
Buy Rating Affirmed for Bio-Techne Amid Market Recovery and Strategic Positioning
Mar 28
9:04am ET
Bio-Techne and Nikon partner for spatial biology services
Mar 22
7:02am ET
Bio-Techne receives European IVDR certification for diagnostic test
Feb 08
9:44am ET
Alibaba downgraded, Disney upgraded: Wall Street’s top analyst calls
Feb 08
7:01am ET
Bio-Techne initiated with an Outperform at Scotiabank on market-leading growth
Feb 07
4:19pm ET
Bio-Techne initiated with an Outperform at Scotiabank
Feb 05
4:05am ET
Bio-Techne: Solid Consumables Business and Strategic Investments Anchor Buy Rating Amid Sector Headwinds
Feb 02
9:37am ET
Macy’s upgraded, New York Community downgraded: Wall Street’s top analyst calls
Feb 02
8:50am ET
Bio-Techne price target lowered to $85 from $88 at Deutsche Bank
Feb 02
8:41am ET
Bio-Techne price target lowered to $80 from $86 at Craig-Hallum
Feb 02
7:40am ET
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), MoonLake Immunotherapeutics (MLTX)
Feb 02
6:49am ET
Bio-Techne price target raised to $73 from $68 at Baird
Feb 02
6:38am ET
Bio-Techne price target lowered to $87 from $92 at Stephens
Feb 02
5:05am ET
Bio-Techne Growth Outlook: Hold Rating Amidst Flat Growth and Valuation Concerns
Feb 02
5:03am ET
Bio-Techne downgraded to Hold from Buy at Stifel
Feb 01
6:43am ET
Bio-Techne reports Q2 adjusted EPS 40c, consensus 41c
Jan 31
8:25pm ET
Notable companies reporting before tomorrow’s open
Jan 31
12:59pm ET
Notable companies reporting before tomorrow’s open
Jan 30
8:36pm ET
Bio-Techne (TECH) Receives a Buy from Craig-Hallum
Jan 26
8:46pm ET
RBC Capital Sticks to Their Hold Rating for Bio-Techne (TECH)
No recent press releases are available for TECH
TECH Financials
Key terms
Ad Feedback
TECH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TECH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range